U.S. patents available from 1976 to present.
U.S. patent applications available from 2005 to present.

PATENT WITHDRAWN
Compositions, methods and devices for the transdermal delivery of drugs

Patent 6214374 Issued on April 10, 2001. Estimated Expiration Date: Icon_subject May 22, 2016. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Patent References

Drug delivery device
Patent #: 3964482
Issued on: 06/22/1976
Inventor: Gerstel ,   et al.

Method for percutaneously administering physiologically active agents using an alcohol adjuvant and a solvent
Patent #: 4590190
Issued on: 05/20/1986
Inventor: Saito ,   et al.

Hydrophilic pressure sensitive biomedical adhesive composition
Patent #: 4593053
Issued on: 06/03/1986
Inventor: Jevne ,   et al.

Transdermal formulation of nicardipine hydrochloride
Patent #: 4637930
Issued on: 01/20/1987
Inventor: Konno ,   et al.

Microphase separated hydrogels for controlled release of bioactive materials
Patent #: 4693887
Issued on: 09/15/1987
Inventor: Shah

Method for percutaneously administering physiologically active agents
Patent #: 4710497
Issued on: 12/01/1987
Inventor: Heller ,   et al.

Skin permeation enhancer compositions using glycerol monolaurate
Patent #: 4746515
Issued on: 05/24/1988
Inventor: Cheng ,   et al.

Method and percutaneously administering physiologically active agents using an alcohol adjuvant and a solvent
Patent #: 4752612
Issued on: 06/21/1988
Inventor: Saito ,   et al.

Transdermal drug delivery system
Patent #: 4797284
Issued on: 01/10/1989
Inventor: Loper ,   et al.

Transdermal fertility control system and process
Patent #: 4818540
Issued on: 04/04/1989
Inventor: Chien ,   et al.

More ...

Abstract

The present invention is directed to compositions, and methods for the delivery of drugs. Devices for the transdermal delivery of drugs are also provided. Specifically, the present invention relates to hydrogel compositions comprising water and a base mixture, in which the base mixture comprises: (i) a gelling agent consisting of methycellulose or at least one natural gum, or a mixture thereof; (ii) at least one natural gum: (iii) glucose; (iv) propylparaben; (v) methyl paraben; and (vi) sodium chloride.The compositions may further comprise pectin, glycolic, alcoholic or oil-based additives, a coloring, fragrance, or other pharmaceutically acceptable additive. The compositions may further comprise substituted ureas of the formula R--NH--CO--NH2 such as butylurea. The compositions may further comprise drugs such as hormones selected from progesterone, progestin, estrogen and testosterone. Methods for the treatment of disorders responsive to hormone therapy are also provided.

Other References

  • Barry and Bennett, "Effect of Penetration Enhancers on the Permeation of Mannitol, Hydrocortisone, and Progesterone Through Human Skin," J. Pharm. Pharmacol. 39:535-546 (1987)
  • Chakmakjan et al., "Biovailability of Progesterone with Different Modes of Administration," The Journal of Reproductive Medicine 32(6):443-447 (Jun. 1987)
  • Chien, "Advances in Transdermal Systemic Drug Delivery," Drugs of the Future, 13(4):343-362 (1988)
  • Ellerington et al., "HRT: Developments in Therapy." British Medical Bulletin, 48(2):401-425 (1992)
  • Feldman et al., "Percutaneous Penetration of Hydrocortisone with Urea," Arch. Dermatol., 109:58-59 (Jan. 1974)
  • Friend, "Transdermal Delivery of Contraceptives," Critical Reviews in Therapeutic Drug Carrier Systems 7(2):149-186 (1990)
  • Guy et al., "Kinetics of Drug Absorption Across Human Skin In Vivo," Pharmacol. Skin 1:70-76 (1987)
  • Han et al., "Percutaneous Absorption-Enhancing Activity of Urea Derivatives," Arch. Pharm. Res. 14(1):12-18 (1991)
  • Hargrove et al., "Menopausal Hormone Replacement Therapy With Continuous Daily Oral Micronized Estradiol and Progesterone," Obstetrics & Gynecology 73(4):606-612 (1989)
  • Knepp et al., "Controlled Drug Release from a Novel Liposomal Delivery System II. Transdermal Delivery Characteristics," 12:25-30 (1990)
  • Li et al., "The Effect of Film-Coating Additives on the In Vitro Dissolution Release Rate of Ethyl Cellulose-Coated Theophylline Granules," Pharmaceutical Technology, pp. 20-24 (Mar. 1990)
  • Maxson, "The Use of Progesterone in the Treatment of PMS," J. Clin. Obstetrics & Gynecology 30(2):465-480 (1987)
  • Peppas, ed., "Hydrogels in Medicine and Pharmacy: vol. III: Properties and Applications," CRC Press, Inc., pp. 95-108 and 151-176 (1987)
  • Peppas, ed., "Hydrogels in Medicine and Pharmacy: vol. II: Polymers," CRC Press, Inc., pp. 65-94 and 115-160 (1987)
  • Pfister et al., "Permeation Enhancers Compatible with Transdermal Drug Delivery Systems: Part II: System Design Considerations," Pharmaceutical Technology, pp. 55-59 (Oct. 1990)
  • Pfister, "Customizing Silicone Adhesives for Transdermal Drug Delivery Systems," Pharmaceutical Technology, p. 126 (Mar. 1989)
  • Scheuplein, J., "Mechanism of Percutaneous Adsorption" Invest. Dermatol. 45:334-346 (1965)
  • Sitruk-Ware, "Transdermal Application of Steroid Hormones for Contraception," J. Steroid Biochem. Molec. Biol. 53(1-6):247-251 (1995)
  • Sitruk-Ware, "Percutaneous and Transdermal Oestrogen Replacement Therapy," Sun. Med. 25:77-82 (1993)
  • Sitruk-Ware, "Transdermal Delivery of Steroids," Contraception 39(1):1-20 (Jan. 1989)
  • Sitruk-Ware, "Innovative Technology for Hormonal Replacement Therapy," Maturitas 10:79-81 (1988)
  • Toddywala et al., "Evaluation of Silicone-Based Pressure Sensitive Adhesives for Transdermal Drug Delivery. I. Effect of Pentrant Hydrophilicity." J. Controlled Release 14:29-41 (1990)
  • Voight et al., "Factors Influencing on the In-Vivo and In-Vitro Liberation of Drugs from Hydrogels," Pharmazie 39(9):618-320 (1984
PatentsPlus Images
Enhanced PDF formats
loading...
PATENT WITHDRAWN
 
Sign InRegister
Username  
Password   
forgot password?